The purpose of this study is to find out if the plasma concentration of donepezil is changed when BMS-708163 is administered at the same time
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
18
Tablets, Oral, 5 mg, Once Daily, Days 1-28
Capsule, Oral, 125 mg, Once Daily, Days 15-28
Parexel International - Baltimore Epcu
Baltimore, Maryland, United States
Aricept® alone and with BMS-708163: Aricept® Multiple-dose pharmacokinetic parameters (Cmax, Tmax, AUC (TAU), and Ctrough) will be assessed without BMS-708163 on Day 14 and with BMS-708163 (Ctrough) on Day 28
Time frame: Days 14 and 28
Aricept® alone and with BMS-708163: Safety and tolerability based on adverse events, ECG, vital signs and safety labs
Time frame: Days 7, 14, 21, 29 and study discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.